3:36 PM
 | 
Nov 10, 2017
 |  BC Extra  |  Clinical News

Novartis details brolucizumab wet AMD data

In a media briefing Friday, Novartis AG (NYSE:NVS; SIX:NOVN) detailed secondary endpoint data from the Phase III HAWK and HARRIER trials of brolucizumab (RTH258) to treat wet age-related macular degeneration (AMD) and touted the candidate's potential dosing advantage over Eylea aflibercept from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Brolucizumab is a next-generation single-chain anti-VEGF antibody fragment.

Novartis said intravitreal 6...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >